Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics

Corneal neovascularization (CoNV) leads to visual impairment, affecting over 1.4 million people in the United States per year. It is caused by a variety of pathologies, such as inflammation, hypoxia, and limbal barrier dysfunction. Injection of the anti-vascular endothelial growth factor (VEGF) drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Wenqi, Sun, Shuo, Tian, Bo, Tai, Phillip W.L., Luo, Yongwen, Ko, Jihye, Zhan, Wei, Ke, Xiao, Zheng, Qiang, Li, Xiaorong, Yan, Hua, Gao, Guangping, Lin, Haijiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413663/
https://www.ncbi.nlm.nih.gov/pubmed/34514023
http://dx.doi.org/10.1016/j.omtm.2021.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413663/
https://www.ncbi.nlm.nih.gov/pubmed/34514023
http://dx.doi.org/10.1016/j.omtm.2021.06.007

Ejemplares similares